3Geng Z, Monier-Faugere MC, Bauss F, et al.Short-term administration of the bisphosphonate ibandrouate increases bone volume and prevents by perparathyroad bone changes in mild inexperimental renal failure[J]. Cliu Nephrol,2000,54(1): 45.
4Hirage T,Williams PJ, Mundy GR, et al.The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases[J]. Cancer-Res,2001,61(11):4418.
5Thiebaud D, Burckhardt P, Kriegbaum H,et al.Three monthly intravenous injections of ibandronate in the treatment of postmenopausal asteoporosis[J]. Am G Med,1997,103(4):298.
3COLEMAN RE, PUROHIT OP. Osteoclast inhibition for the treatment of bone metastases [J].Cancer Treat Rev, 1993,19(1):79 - 103.
4HILLNER BE, INGLE JN, BERENSON JR,et al. American Society of Clinical Oncology Guideline On the role of bisphosphonates in breast cancer,American Society of Clinical Oncology Bisphosphonates Expert Panel [J]. J Chin Oncol, 2000, 18(6) :1378 - 1391.
5BERENSON JR ,HILLNER BE, KYLE RA, et al. American Society of Clinical Oncology Clinical Practice guideline:The role of bisphosphonates in multiple myeloms [J] . J Clin Oncol, 2002,20(17) :3719 -3736.
6Green JR,Muuerk,Jaeggi KA.Preclinical pharmacology of Gcp 42466,a new potent heterocyclic bishosphonate compound.Bone Miner Res,1994,9:745-750.
7Sharma P B, Lal B M. Studies on the nutritional quality of some cucurtbit kernel proteins [ J]. Sci. Food and Agric.,1986,37:418 - 420.
8Coleman R I, Purohit 0 P. Osteoclast inhibition for the treatment of bone metastases [ J ]. Cancer Treat Rev, 1993,19:79 - 203.
9Hillner B E, Ingle J N, Berenson J R, et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer, American Society of Clinical Oncology Bisphosphonates Expert Panel [ J]. J Clin Oncol,2000, 18(6) :1378 - 1391.
10Berenson J R, Hillner B E, Kyle R A,et al. American society of clinical oncology clinical practice guideline: the role of bisphosphonates in multiple myeloms [ J ]. J Clin Oncol,2002,20( 17 ) : 3719 - 3736.
